Recent trends in mortality from benign prostatic hyperplasia

Prostate

Volumn 56, Issue 3, 2003, Pages 207-211

  Levi, Fabio ^a,e   Lucchini, Franca ^a   Negri, Eva ^b   Boyle, Peter ^c   La Vecchia, Carlo ^a,b,d  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b Laboratory of Epidemiology   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e Vaud Cancer Registry   (Switzerland)

Author keywords

Benign prostatic hyperplasia; Mortality; Trends

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; DEATH CERTIFICATE; DEVELOPED COUNTRY; EASTERN EUROPE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREVALENCE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; UNITED STATES; WORLD HEALTH ORGANIZATION;

AGED; DATABASES, FACTUAL; DEATH CERTIFICATES; EUROPE; HUMANS; JAPAN; MALE; MIDDLE AGED; MORTALITY; PROSTATIC HYPERPLASIA; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 0042671451     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10250     Document Type: Article

References (13)

1. La Vecchia C, Levi F, Lucchini F. Mortality from benign prostatic hyperplasia: Worldwide trends 1950-92. J Epidemiol Community Health 1995;49:379-384.
2. Boyle P, Maisonneuve P, Steg A. Decrease in mortality from benign prostatic hyperplasia: A major unheralded health triumph. J Urol 1996;155:176-180.
3. Boyle P, Keech M, Nonis A, Fourcade R, Hobbs R, Kiemeney A, Lee C, Maier W, Watson M, Barry M, Robertson C. The UrEpiK study: A cross-sectional survey of benign prostatic hyperplasia, urinary incontinence and male erectile dysfunction, prostatitis and interstitial cystitis in the UK, France, the Netherlands and Korea. J Epidemiol Biostat 1998;3:179-187.
4. Apolone G, Cattaneo A, Colombo P, La Vecchia C, Cavazzuti L, Bamfi F. Knowledge and opinion on prostate and prevalence of self-reported BPH and prostate-related events. A cross-sectional survey in Italy. Eur J Cancer Prev 2002;11:473-479.
5. Levi F, Lucchini F, Negri E, La Vecchia C. Recent trends in prostate cancer mortality in the European Union. Epidemiology 2000;11:612.
6. Tarone RE, Chu KC, Brawley OW. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology 2000;11:167-170.
7. Wilt TJ. Treatment options for benign prostatic hyperplasia. Br Med J 2002;324:1047-1048.
8. Jepsen JV, Bruskewitz RC. Recent developments in the surgical management of benign prostatic hyperplasia. Urology 1998; 51(Suppl 4A):23-31.
9. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS, Vaughan ED, Pappas F, Taylor A, Binkowitz B, Ng J. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992;327:1185-1191.
10. Clifford GM, Farmer RDT. Medical therapy for benign prostatic hyperplasia: A review of the literature. Eur Urol 2000;38:2-19.
11. Stoevelaar HJ, McDonnell J. Changing therapeutic regimens in benign prostatic hyperplasia. Clinical and economic considerations. Pharmacoeconomics 2000;19:131-153.
12. Levi F, La Vecchia C, Boyle P, Lucchini F, Negri E. Western and eastern European trends in testicular cancer mortality. Lancet 2001;357:1853-1854.
13. Levi F, Lucchini F, Boyle P, Negri E, La Vecchia C. Testicular cancer mortality in casteru Europe. Int J Cancer 2003;A05:574.